Exciting news this morning - as we enter a Cooperative Research and Development Agreement (CRADA) with NCATS to investigate AZM-152 in BPD! These IND enabling studies will help us get closer to helping thousands of families currently impacted by this severe lung condition that affects about 15,000 preterm infants each year. Read more here: https://lnkd.in/ghpi79mM. #medtech #lifesciences #innovations #biotech #TechTransfer #entrepreneur #UFresearch Rashmin Savani Elliott A. Gruskin PhD BioFlorida, Inc.
Azome Therapeutics
生物技术研究
Developing selective NLRP3 inflammasome inhibitors for severe inflammatory diseases
关于我们
Azome Therapeutics is an early-stage drug discovery company focused on developing selective antagonists of the NLRP3 inflammasome, an inflammatory pathway critical to the development of a wide variety of diseases. Our lead candidate, AZM-152, is a RHAMM-derived antagonist that blocks a key upstream priming signal involved in the aberrant activation of the NLRP3 inflammatory cascade.
- 网站
-
https://azometherapeutics.com
Azome Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 类型
- 私人持股
- 创立
- 2023
Azome Therapeutics员工
动态
-
Azome Therapeutics Presents at 6th Annual Inflammasome Therapeutics Summit Head of Scientific Advisory Board Dr. Rashmin Savani and CEO Elliott Gruskin among expert speakers on inflammasome targeting in drug development at the three-day biopharma summit. Visit the link below to learn more: https://bit.ly/4grHTyr
-
Elliott A. Gruskin PhD Gruskin is looking forward to sharing Azome Therapeutics groundbreaking work! Rashmin Savani
Join us as these early stage start-up companies take the stage to present their groundbreaking technologies and innovations live at #BioNJ’s BioPartnering Conference. Spots are filling up quickly – Register Today! https://ow.ly/vitH50RBWme 6S Pharma LLC. Abonics India Private Limited Addinex Technologies, Inc.Advent Therapeutics, Inc.Aperture Bio Azome Therapeutics BioLattice Delphine Diagnostics Inc Dimer Health HopeAI Inaedis, Inc. Innerstill InteguRx Therapeutics LLC Kognitic, Inc. KolateAI PharmaTech Inc LumaCell Systems Materialize Bio Mechano-Therapeutics LLC Monarch Therapeutics, Inc. NeuroPAIR OLITECHNOLOGY Orbits Oncology Pression PRIMA INNOVATIONS LLC SciMar ONE Synergy Therapeutics tenXclinical Vasowatch VITRUVIAE Zena Therapeutics Inc.
-
-
CEO Elliott Gruskin will be presenting at the BioNJ Biopartnering Conference on May 14, where he will highlight the company’s RHAMM (Receptor for Hyaluronan-Mediated Motility) antagonist technology platform and its lead drug candidate, AZM-152. Read more: https://lnkd.in/ghWtpcVa
-
-
Azome Therapeutics Scientific Advisory Board Head Dr. Rashmin Savani recently gave a keynote speech at the Third Annual Meeting, 9th Congress of the Taiwan Society of Pediatric Pulmonology and Critical Care Medicine.? Dr. Savani’s presentation, "Lung Injury and Inflammation in BPD: Mechanisms and Novel Therapeutics,” featured the latest data supporting the development of the company’s RHAMM (Receptor for Hyaluronan-Mediated Motility) antagonist technology platform to treat severe inflammatory diseases such as BPD and ARDS.
-